SRD5A2 and emerging therapies in androgen-driven disorders

Area of Science:

• Urology
• Endocrinology
• Molecular Biology

Background:

• Benign prostatic hyperplasia (BPH) is a common urological condition in aging men.
• Current medical therapies for BPH have limitations in long-term effectiveness.
• 5α-reductase inhibitors (5ARIs) are frequently prescribed to manage BPH symptoms and progression.

Purpose of the Study:

• To investigate the role of steroid 5α-reductase (SRD5A) enzymes, particularly SRD5A2, in BPH pathogenesis.
• To explore SRD5A2 alterations as potential biomarkers for personalized BPH therapy.
• To assess the clinical relevance of SRD5A2 in BPH, prostate cancer, and androgenic alopecia.

Main Methods:

• Inhibition of SRD5A enzymes, focusing on SRD5A1 and SRD5A2 isoforms.
• Analysis of SRD5A2's role in androgen metabolism and prostate growth.
• Examination of genetic polymorphisms, epigenetic silencing, and inflammation-induced changes in SRD5A2.

Main Results:

• SRD5A2 is the dominant isoform in the prostate, crucial for converting testosterone to dihydrotestosterone.
• SRD5A2 plays a key role in maintaining the balance of androgenic and oestrogenic signaling.
• Alterations in SRD5A2 are associated with BPH risk and progression, suggesting biomarker potential.

Conclusions:

• SRD5A2 is clinically relevant in BPH, prostate cancer, and other androgen-mediated conditions.
• SRD5A2 alterations present opportunities for developing personalized therapeutic strategies.
• Overcoming limitations in SRD5A2-targeted therapies is essential for improving 5ARI efficacy.